Gilead Sciences (GILD) reported $29.4B in revenue for fiscal 2025, +2.4% year on year. That ranks #183 by revenue among 2853 SEC filers and #24 in Healthcare. Net income was $8.5B, a net margin of 28.9%. Revenue has grown 9.4% a year on average since 2011 ($8.4B then). The fiscal 2025 balance sheet shows $59.0B in total assets, $7.6B in cash and $22.1B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $29.4B | +2.4% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $10.0B | +503.0% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $8.5B | +1,672.9% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $10.0B | −7.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $563M | +7.6% | FY20252025-12-31 |
| Total assetsAssets | $59.0B | +0.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $22.7B | +17.4% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $7.6B | −24.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $22.1B | −11.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $7.0B | $2.0B | Open → |
| Q2 20262026-06-30 | $7.8B | −$10.5B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 11 of 161 companies compared | 28.9% | |
| Operating marginRank 11 of 160 companies compared | 34.0% | |
| R&D as share of revenueRank 26 of 102 companies compared | 19.7% | |
| Cash as share of revenueRank 36 of 160 companies compared | 25.7% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Gilead Sciences, Inc.
- Ticker
- GILD
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0000882095
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| GSKGSK | $43.1B | $7.5B |
| AmgenAMGN | $36.8B | $7.7B |
| MedtronicMDT | $36.4B | $4.8B |
| Gilead SciencesGILD | $29.4B | $8.5B |
| MedlineMDLN | $28.4B | $1.2B |
| StrykerSYK | $25.1B | $3.2B |
| 3MMMM | $24.9B | $3.3B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Gilead Sciences — Key figures |url=https://companiesranked.com/en/company/gilead-sciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Gilead Sciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/gilead-sciencesBibTeX
@misc{companiesranked-en-company-gilead-sciences-2026,
author = {{CompaniesRanked}},
title = {{Gilead Sciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/gilead-sciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000882095-26-000006 · February 24, 2026
{{cite web |title=Gilead Sciences — Key figures — 10-K (0000882095-26-000006) |url=https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.